Portola Pharmaceuticals Announces New Analysis From The Annexa-4 Study Of Its Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Spontaneous Intracranial Hemorrhage; Excellent Or Good Hemostasis Achieved In 79% Of Evaluable Patients